The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled ``Delayed Graft Function in Kidney Transplantation: Developing Drugs for Prevention.'' The purpose of this guidance is to assist sponsors in the clinical development of drugs for the prevention of delayed graft function (DGF) in kidney transplantation.
Document
Delayed Graft Function in Kidney Transplantation: Developing Drugs for Prevention; Draft Guidance for Industry; Availability
The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled ``Delayed Graft Function in Kidney Transplantation: Dev...
Legal Citation
Federal Register Citation
Use this for formal legal and research references to the published document.
82 FR 14904
Web Citation
Suggested Web Citation
Use this when citing the archival web version of the document.
“Delayed Graft Function in Kidney Transplantation: Developing Drugs for Prevention; Draft Guidance for Industry; Availability,” thefederalregister.org (March 23, 2017), https://thefederalregister.org/documents/2017-05818/delayed-graft-function-in-kidney-transplantation-developing-drugs-for-prevention-draft-guidance-for-industry-availabilit.